{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:23:37Z","timestamp":1778801017491,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0903-6","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:04:44Z","timestamp":1536591884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Monica","family":"Hadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Swinburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luba","family":"Nalysnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, Shields AL. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient preference and adherence. 2016;10:1609\u201321.","journal-title":"Patient preference and adherence"},{"key":"903_CR2","first-page":"923","volume":"9","author":"J J-f","year":"2015","unstructured":"J-f J, L-l Z, Chen M, H-m X, H-f W, X-q F, X-p Z, Zhou Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence. 2015;9:923\u201342.","journal-title":"Patient preference and adherence"},{"key":"903_CR3","first-page":"59","volume":"2","author":"TA Burrow","year":"2011","unstructured":"Burrow TA, Barnes S, Grabowski GA. Prevalence and management of Gaucher disease. Pediatric Health, Medicine and Therapeutics. 2011;2:59\u201373.","journal-title":"Pediatric Health, Medicine and Therapeutics"},{"key":"903_CR4","unstructured":"Gaucher disease [ http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=EN&Expert=355 ]."},{"key":"903_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bjh.12804","volume":"165","author":"AS Thomas","year":"2014","unstructured":"Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165:427\u201340.","journal-title":"Br J Haematol"},{"key":"903_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/2230-8210.83402","volume":"15","author":"V Bohra","year":"2011","unstructured":"Bohra V, Nair V. Gaucher's disease. Indian J Endocrinol Metab. 2011;15:182\u20136.","journal-title":"Indian J Endocrinol Metab"},{"key":"903_CR7","volume-title":"Enzyme-Replacement Therapies for Lysosomal Storage Diseases","author":"TA Ratko","year":"2013","unstructured":"Ratko TA, Marbella A, Godfrey S, Aronson N. Enzyme-Replacement Therapies for Lysosomal Storage Diseases. Rockville (MD): AHRQ Comparative Effectiveness Technical Briefs; 2013."},{"key":"903_CR8","first-page":"81","volume":"6","author":"PB Deegan","year":"2012","unstructured":"Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81\u2013106.","journal-title":"Drug Des Devel Ther"},{"key":"903_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.clinthera.2011.12.017","volume":"34","author":"JL Morris","year":"2012","unstructured":"Morris JL. Velaglucerase alfa for the management of type 1 Gaucher disease. Clin Ther. 2012;34:259\u201371.","journal-title":"Clin Ther"},{"key":"903_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2014.02.011","volume":"112","author":"GA Grabowski","year":"2014","unstructured":"Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab. 2014;112:1\u20138.","journal-title":"Mol Genet Metab"},{"key":"903_CR11","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385:2355\u201362.","journal-title":"Lancet"},{"key":"903_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313:695\u2013706.","journal-title":"JAMA"},{"key":"903_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1750-1172-7-102","volume":"7","author":"TM Cox","year":"2012","unstructured":"Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study G. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102.","journal-title":"Orphanet J Rare Dis"},{"key":"903_CR14","unstructured":"Drugs@FDA: FDA Approved Drug Products - Cerdelga (eliglustat tartrate) [ http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=205494 ]."},{"key":"903_CR15","unstructured":"European public assessment report (EPAR) for Cerdelga (eliglustat) last updated on 21\/04\/2015 [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003724\/human_med_001840.jsp&mid=WC0b01ac058001d124 ]."},{"key":"903_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"JK Hicks","year":"2013","unstructured":"Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC, Clinical Pharmacogenetics Implementation C. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"903_CR17","doi-asserted-by":"crossref","unstructured":"Judith Peterschmitt M, Cox GF, Ibrahim J, MacDougall J, Underhill LH, Patel P, Gaemers SJ. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration. Blood Cells Mol Dis. 2017;","DOI":"10.1016\/j.bcmd.2017.01.006"},{"key":"903_CR18","unstructured":"European public assessment report (EPAR) for Zavesca (miglustat) last updated on 13\/09\/2016 [ http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000435\/human_med_001171.jsp&mid=WC0b01ac058001d124 ]."},{"key":"903_CR19","unstructured":"Drugs@FDA: FDA Approved Drug Products - Zavesca (miglustat) [ http:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021348 ]."},{"key":"903_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/j.1463-1326.2012.01595.x","volume":"14","author":"M Davies","year":"2012","unstructured":"Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:882\u201392.","journal-title":"Diabetes Obes Metab"},{"key":"903_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11096-012-9729-9","volume":"35","author":"S Russell","year":"2013","unstructured":"Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm. 2013;35:159\u201372.","journal-title":"Int J Clin Pharm"},{"key":"903_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","volume":"29","author":"MD Cappellini","year":"2007","unstructured":"Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29:909\u201317.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"903_CR23","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","volume":"12","author":"MC Weinstein","year":"2009","unstructured":"Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5\u20139.","journal-title":"Value Health"},{"key":"903_CR24","first-page":"118","volume":"7","author":"GW Torrance","year":"1972","unstructured":"Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118\u201333.","journal-title":"Health Serv Res"},{"key":"903_CR25","unstructured":"Guide to the methods of technology appraisal 2013 [ https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword ]."},{"key":"903_CR26","first-page":"1561","volume":"9","author":"BA Fordham","year":"2015","unstructured":"Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, Tremblay G, Forsythe A, McIver B, Cohen EE. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015;9:1561\u201372.","journal-title":"Patient Prefer Adherence"},{"key":"903_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683\u201390.","journal-title":"Br J Cancer"},{"key":"903_CR28","unstructured":"2011 Census: Key Statistics for England and Wales, March 2011 [ http:\/\/www.ons.gov.uk\/ons\/rel\/census\/2011-census\/key-statistics-for-local-authorities-in-england-and-wales\/stb-2011-census-key-statistics-for-england-and-wales.html ]."},{"key":"903_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"issue":"Suppl 1","key":"903_CR30","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s10198-013-0508-x","volume":"14","author":"AE Attema","year":"2013","unstructured":"Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):S53\u201364.","journal-title":"Eur J Health Econ"},{"key":"903_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0272989X09357475","volume":"30","author":"C Tilling","year":"2010","unstructured":"Tilling C, Devlin N, Tsuchiya A, Buckingham K. Protocols for time tradeoff valuations of health states worse than dead: a literature review. Med Decis Mak. 2010;30:610\u20139.","journal-title":"Med Decis Mak"},{"key":"903_CR32","volume-title":"UK Population Norms for EQ-5D. . Centre for health economics, University of York","author":"P Kind","year":"1999","unstructured":"Kind P, Hardman G, Macran S: UK Population Norms for EQ-5D. . Centre for health economics, University of York; 1999."},{"key":"903_CR33","doi-asserted-by":"crossref","unstructured":"Feeny D: Preference-based measures: utility and quality-adjusted life years, chapter 6.2 in Assessing Quality of Life in Clinical Trials. Second edition edition. Edited by Peter Fayers and Ron hays e: Oxford University Press; 2005: 405\u2013429.","DOI":"10.1093\/oso\/9780198527695.003.0025"},{"key":"903_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1185\/03007990802077442","volume":"24","author":"J Karnon","year":"2008","unstructured":"Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin. 2008;24:1609\u201321.","journal-title":"Curr Med Res Opin"},{"key":"903_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1524-4733.2007.00200.x","volume":"10","author":"RH Osborne","year":"2007","unstructured":"Osborne RH, De Abreu Lourenco R, Dalton A, Houltram J, Dowton D, Joshua DE, Lindeman R, Ho PJ. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007;10:451\u20136.","journal-title":"Value Health"},{"key":"903_CR36","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00019053-199610060-00008","volume":"10","author":"ES Johnson","year":"1996","unstructured":"Johnson ES, Sullivan SD, Mozaffari E, Langley PC, Bodsworth NJ. A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. PharmacoEconomics. 1996;10:623\u20139.","journal-title":"PharmacoEconomics"},{"key":"903_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2174\/1874924000902010026","volume":"2","author":"H Sakamaki","year":"2009","unstructured":"Sakamaki H, Ikeda S, Yajima S, Ikegami N, Tanaka K, Shimizu H, Murayama JI. Cost-utility analysis of the oral Fluoropyrimidine S-1 versus conventional intravenous chemotherapy in advanced or recurrent gastric Cancer. The Open Health Services and Policy Journal. 2009;2:26\u201333.","journal-title":"The Open Health Services and Policy Journal"},{"key":"903_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/03007995.2016.1232704","volume":"33","author":"AJ Lloyd","year":"2017","unstructured":"Lloyd AJ, Gallop K, Ali S, Hughes D, MacCulloch A. Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment. Curr Med Res Opin. 2017;33:23\u20139.","journal-title":"Curr Med Res Opin"},{"key":"903_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-017-0592-6","volume":"12","author":"ML Ganz","year":"2017","unstructured":"Ganz ML, Stern S, Ward A, Nalysnyk L, Selzer M, Hamed A, Weinreb N. A new framework for evaluating the health impacts of treatment for Gaucher disease type 1. Orphanet Journal of Rare Diseases. 2017;12:38.","journal-title":"Orphanet Journal of Rare Diseases"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0903-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T04:44:20Z","timestamp":1720586660000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0903-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0903-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LN and AH are employees of Sanofi Genzyme. MH and PS, employees of Mapi at the time this study was conducted, were paid consultants to Sanofi Genzyme. AM is a Professor and Clinical Director at Lysosomal Storage Disorders Unit, Department of Haematology, Royal Free Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"159"}}